September 30th, 2013
Stephen Gottlieb discusses his research group’s analysis of ASCEND-HF data, which shows that nesiritide does not increase urine output in patients with ADHF.
August 18th, 2013
Chohreh Partovian discusses her research group’s study of how hospitals varied in their responses to safety concerns about nesiritide from 2005 to 2010.
October 6th, 2011
The U.S. Department of Justice announced that Johnson & Johnson has pleaded guilty to a misdemeanor and has agreed to pay an $85 million criminal fine to settle charges about the company’s marketing of Natrecor (nesiritide) for off-label use. The government said that Scios, the J&J subsidiary that marketed the drug, “admitted that it intended Natrecor to […]
July 7th, 2011
With the publication of the final results of the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial in the New England Journal of Medicine, the once intense controversy over the use — or misuse — of the drug nesiritide in patients with acute decompensated heart failure has finally been resolved. […]
November 30th, 2010
Results of ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial), presented as a late-breaking clinical trial at the AHA meeting, showed that there were no significant differences in the pre-specified endpoint of dyspnea among some 7,000 patients with acute, decompensated HF randomized to receive standard therapy and either continuous intravenous nesiritide or placebo. This trial was started in […]
November 14th, 2010
ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial) was started in response to the enormous controversy over the safety and efficacy of nesiritide, which was being used in growing numbers of heart failure patients. The trial randomized 7141 patients with acute, decompensated HF to receive standard therapy and either continuous intravenous nesiritide or placebo. Results of ASCEND-HF, presented as a […]